• Use of a Powered Arm Support Device for Upper Limb Function in Non-Ambulatory Men with Duchenne Muscular Dystrophy

    Brief Description: Brief Description:  This study is a longitudinal, randomized comparison trial evaluating the use of two commercially available dynamic arm support devices (Armon Ayura-O540 and JAECO WREX) to promote participation in activities of daily living in non-ambulatory individuals with Duchenne muscular dystrophy (DMD) with upper extremity weakness. Up to 30 individuals will be enrolled to participate in this research study, which includes a two-week baseline data collection period, a four-week device trial and a two-week post device data collection period. Participants will be randomly assigned to trial one of the dynamic arm support devices during the four week in-home trial, with the potential for a cross-over trial with the non-randomized device. The ActiGraph, a wrist worn activity monitoring device, will be worn during the baseline period, the device trial and the post device data collection period to capture UE movement patterns. UE performance will be further quantified with use of a physical motor assessment, the Performance of Upper Limb (PUL) assessment and patient reported outcomes. Data gleaned will provide important knowledge and objective results regarding the potential benefit of dynamic arm supports in individuals with DMD with limited functional use of their upper extremities. To learn more about the study eligibility and participating sites, please visit  or contact Dr. Roxanna Bendixen ( for additional information.
  • Community Based Outcome Measures in Boys with DMD

    Brief Description: Participants are being invited to take part in this parallel research study if they are enrolled in VBP15 2b clinical trial for boys with Duchenne Muscular Dystrophy (DMD). This study requests boys enrolled in VBP 15 wear the ActiGraph GT9x, a wrist-worn portable fitness tracking device, to objectively explore sleep factors and daily physical activity throughout the clinical trial. Patient reported outcomes regarding sleep and daily participation will also be collected. To learn more about the study eligibility please contact Dr. Roxanna Bendixen (
  • Long-Term Observational Study of Translarna Safety and Effectiveness in Usual Care

    Brief Description: This is a Phase IV, multicenter, observational study being performed as a post-approval safety study (PASS) to assess the long-term clinical benefit of Translarna (Ataluren) when used in routine clinical practice. Ataluren which is being marketed as Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in patients aged 2 years and older. Enrolled patients will be followed for at least 5 years from the date of enrollment, or until withdrawal from the study. To learn more about the study eligibility and participating sites please visit: